Synthesis of novel GABA uptake inhibitors. 4. Bioisosteric transformation and successive optimization of known GABA uptake inhibitors leading to a series of potent anticonvulsant drug candidates

Journal of Medicinal Chemistry

Volumn 42, Issue 21, 1999, Pages 4281-4291

  Andersen, Knud Erik ^a   Sørensen, Jan L ^a   Huusfeldt, Per O ^a   Knutsen, Lars J S ^a,b   Lau, Jesper ^a   Lundt, Behrend F ^a   Petersen, Hans ^a,c   Suzdak, Peter D ^a,d   Swedberg, Michael D B ^a,e  

^a NOVO NORDISK A S   (Denmark)

^b Cerebrus Limited   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

^d GUILFORD PHARMACEUTICALS INC   (United States)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (3,3 DIPHENYL 1 PROPYLOXY)ETHYL] 3 PIPERIDINECARBOXYLIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ANTICONVULSIVE AGENT; TIAGABINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSFORMATION; FEMALE; MOUSE; NONHUMAN; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTICONVULSANTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS; RATS; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; SYNAPTOSOMES;

EID: 0032742433     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980492e     Document Type: Article

References (66)

1. Knutsen, L. J. S.; Andersen, K. E.; Lau, J.; Lundt, B. F.; Henry, R. F.; Morton, H. E.; Nærum, L.; Petersen, H.; Stephensen, H.; Suzdak, P. D.; Swedberg, M. D. B.; Thomsen, C.; Sørensen, P. O. Synthesis of Novel GABA Uptake Inhibitors. 3. Diaryloxime and Diarylvinyl Ether Derivatives of Nipecotic Acid and Guvacine as Anticonvulsant Agents. J. Med. Chem. 1999, 42, 3447-3462.
2. Enna, S. J. Int. Rev. Neurobiol. 1983, 24, 181-214.
3. Enna, S. J. Biochemistry, Anatomy, and Pharmacology of GABA Neurons. In Psychopharmacology: The Third Generation of Progress; Melzer, H. Y., Ed.; Raven Press: New York, 1987; pp 265-278.
4. Lloyd, K. G.; Morselli, P. L. Biochemistry, Anatomy, and Pharmacology of GABA Neurons. In Psychopharmacology: The Third Generation of Progress; Melzer, H. Y., Ed.; Raven Press: New York, 1983; pp 183-201.
5. Krogsgaard-Larsen, P. GABA Synaptic Mechanisms: Stereo-chemical and Conformational Requirements. Med. Res. Rev. 1988, 8, 27-56.
6. Löscher, W. GABAmimetics in Animal Models of Seizure States. In Epilepsy and GABA Receptor Agonists Basic and Therapeutic Research (L.E.R.S. Monograph Series Vol. 3); Bartholoni, G., Bossi, L., Lloyd, K. G., Morselli, P. L., Eds.; Raven Press: New York, 1985; pp 109-119.
7. Fahn, S. GABA. In GABA in Nervous System Function; Chase, T., Tower, D., Eds.; Raven Press: New York, 1976; p 169.
8. Petty, F.; Coffmann J. A. Neuropharmacology 1984, 23, 859-871.
9. Rebak, C. E.; Hansen, A. B.; Andersen, L.; Vaughan, J. E.; Roberts, E. Science 1979, 205, 211-215.
10. Ross, S. M.; Craig, C. R. J. Neurochem. 1981, 36, 1006-1011.
11. Krogsgaard-Larsen, P. γ-Aminobutyric Acid Agonists, Antagonists, and Uptake Inhibitors. Design and Therapeutic Aspects. J. Med. Chem. 1981, 24, 1377-1383.
12. Krogsgaard-Larsen, P.; Hjeds, H.; Falch, E.; Joergensen, F. S.; Nielsen, L. Recent Advances in GABA Agonists, Antagonists and Uptake Inhibitors: Structure-Activity Relationships and Therapeutic Potential. Adv. Drug. Res. 1988, 17, 381-456.
13. Schechter, P. J. Vigabatrin. In New Anticonvulsant Drugs; Meldrum, B. S., Porter, R. J., Eds.; John Libby: London, 1986; pp 265-275.
14. Lewis, P. J.; Richens, A. Vigabatrin: A New Anti-Epileptic. Br. J. Clin. Pharmacol. 1989, 27.
15. Krogsgaard-Larsen, P.; Falch, E.; Larsson, O. M.; Schousboe, A. GABA Uptake Inhibitors; Relevance to Antiepileptic Drug Research. Epilepsy Res. 1987, 1, 77-93.
16. Hoehn-Saric, R. Effects of THIP on Chronic Anxiety. Psychopharmacology 1983, 80, 338-341.
17. Dhar, T. G. M.; Borden, L. A.; Tyagarajan, S.; Smith, K. E.; Branchek, T. A.; Weinshank, R. L.; Gluchowski, C. Design, Synthesis and Evaluation of Substituted Triarylnipecotic Acid Derivatives as GABA Uptake Inhibitors: Identification of a Ligand with Moderate Affinity and Selectivity for the Cloned Human GABA Transporter GAT-3. J. Med. Chem. 1994, 37, 2334-2342.
18. Krogsgaard-Larsen, P.; Labouta, I. M.; Meldrum, B.; Croucher, M.; Schousboe, A. GABA Uptake Inhibitors as Experimental Tools and Potential Drugs in Epilepsy Research. In Neurotransmitters, Seizures and Epilepsy; Morselli, P., Lloyd, K. G., Löscher, W., Meldrum, B. S., Reynolds, E. H., Eds.; Raven Press: New York, 1981; pp 23-25.
19. Nielsen, L.; Brehm, L.; Krogsgaard-Larsen, P. GABA Agonists and Uptake Inhibitors. Synthesis, Absolute Stereochemistry, and Enantioselectivity of (R)-(-)- and (S)-(+)-Homo-β-proline. J. Med. Chem. 1990, 33, 71-77.
20. Johnston, G. A. R.; Allan, R. D.; Kennedy, S. M. G.; Twitchin, B. Systematic Study of GABA Analogues of Restricted Conformation. In GABA-Neurotransmitters: Pharmaco-chemical Biochemical and Pharmacological Aspects; Krogsgaard-Larsen, P., Scheel-Krüger, J., Kofoed, H., Eds.; Munksgaard: Copenhagen, 1978; pp 147-164.
21. Myers, R. D. Blood-Brain Barrier: Techniques for the Intracerebral Administration of Drugs. In Handbook of Pharmacology, Vol. II; Iversen, L. L., Iversen, S. D., Snyder, S. H., Eds.; Plenum Press: New York, 1975; pp 1-28.
22. Bodor, N.; Brewster, M. E. Problems of Delivery of Drugs to the Brain. Pharmacol. Ther. 1983, 19, 337-386.
23. Yunger, L. M.; Fowler P. J.; Zarevics, P.; Setler, P. E. Novel Inhibitors of γ-Amino-butyric Acid (GABA) Uptake: Anticonvulsant Actions in Rats and Mice. J. Pharmol. Exp. Ther. 1984, 228, 109-115.
24. Braestrup, C.; Nielsen, E. B.; Wolffbrandt, K. H.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U. Modulation of GABA Receptor Interaction with GABA Uptake Inhibitors. Int. Congr. Ser.-Excerpta Med. 1987, 750 (Pharmacology), 125-128.
25. Braestrup, C.; Nielsen, E. B.; Sonnewald, U.; Knutsen, L. J. S.; Andersen, K. E.; Jansen, J. A.; Frederiksen, K.; Andersen, P. H.; Mortensen, A.; Suzdak, P. D. (R)-N-[4,4-Bis(3-Methyl-2-Thienyl)but-3-en-1-yl]Nipecotic Acid Binds with High Affinity to the Brain γ-Aminobutyric Acid Uptake Carrier. J. Neurochem, 1990, 54, 639-647.
26. Nielsen, E. B.; Suzdak, P. D.; Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U.; Braestrup, C. Characterization of tiagabine (NO-328), a New Potent and Selective GABA Uptake Inhibitor. Eur. J. Pharmacol. 1991, 196, 257-266.
27. Löscher, W. Anticonvulsant Action in the Epileptic Gerbil of Novel Inhibitors of GABA Uptake. Eur. J. Pharmacol. 1985, 110, 103-108.
28. Ali, F. E.; Bondinell, W. E.; Danbridge, P. A.; Frazee, J. S.; Garvey, E.; Girard, G. R.; Kaiser, C.; Ku, T. W.; Lafferty, J. J.; Moonsammy, G. I.; Oh, H.-J.; Rush, J. A.; Setler, P. E.; Stringer, O. D.; Venslavsky, J. W.; Volpe, B. W.; Yunger, L. M.; Zirkle, C. L. Orally Active and Potent Inhibitors of Gamma Aminobutyric Acid Uptake. J. Med. Chem. 1985, 28, 653-660.
29. Löscher, W.; Schmidt, D. Which Animal Models Should Be Used in the Search for New Antiepileptic Drugs? A Proposal Based on Experimental and Clinical Considerations. Epilepsy Res. 1988, 2, 145-181.
30. Schwark, W.; Haluska, M. Prophylaxis of Amygdala-Kindling Induced Epileptogenesis: Comparison of a GABA Uptake Inhibitor and Diazepam. Epilepsy Res. 1987, 1, 63-69.
31. Pavia, M. R.; Lobbestael, S. J.; Nugiel D.; Mayhugh, D. R.; Gregor, V. E.; Taylor, C. P.; Schwarz, R. D.; Brahce, L.; Vartanian, M. G. Structure-Activity Studies on Benzhydrol-Containing Nipecotic Acid and Guvacine Derivatives as Potent, Orally-Active Inhibitors of GABA Uptake. J. Med. Chem. 1992, 35, 4238-4248.
32. Bjorge, S.; Black, A.; Bockbrader, H.; Chang, T.; Gregor, V. E.; Lobbestael, S. J.; Nugiel, D.; Pavia, M. R.; Radulovic, L.; Woolf, T. Synthesis and Metabolic Profile of CI-966: A Potent, Orally-Active Inhibitor of GABA Uptake. Drug Dev. Res. 1990, 21, 189-193.
33. Taylor, C. P.; Vartanian, M. G.; Schwarz, R. D.; Rock, D. M.; Callahan, M. J.; Davis, M. D. Pharmacology of CI-966: A Potent GABA Uptake Inhibitor, In Vitro and in Experimental Animals. Drug Dev. Res. 1990, 31, 195-215.
34. N'Goka, V.; Schlewer, G.; Linget, J.-M.; Chambon, J.-P.; Wermuth, C.-G. GABA Uptake Inhibitors. Construction of a General Pharmacophore Model and Successful Prediction of a New Representative. J. Med. Chem. 1991, 34, 2547-2557.
35. Falch, E.; Krogsgaard-Larsen, P. GABA Uptake Inhibitors. Syntheses and Structure-activity Studies on GABA Analogues Containing Diarybutenyl and Diarylmethoxy-alkyl N-substituents. Eur. J. Med. Chem. 1991, 26, 69-78.
36. Fleischhacker, W.; Lauritz, S.; Urban, E.; Baumann, P.; Bittiger, H. Synthesis and biochemical studies of spirocyclic amino acids. II. Activity of 2-azaspiro[5.5]undecane-7-carboxylates as GABA-Uptake Inhibitors. Eur. J. Med. Chem. 1995, 30, 707-713.
37. Taylor, C. P. GABA Receptors and GABAergic Synapses as Targets for Drug Development. Drug Dev. Res. 1990, 21, 151-160.
38. Andersen, K. E.; Braestrup, C.; Gronwald, F. C.; Jorgensen, A. S.; Nielsen, E. B.; Sonnewald, U.; Sorensen, P. O.; Suzdak, P. D.; Knutsen, L. J. S. The Synthesis of Novel GABA Uptake Inhibitors, Part 1. Elucidation of the Structure-Activity Studies leading to the choice of R-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid (tiagabine) as an Anticonvulsant Drug Candidate. J. Med. Chem. 1993,36, 1716-1725.
39. Andersen, K. E.; Begtrup, M.; Choghade, M. S.; Lee, E. C.; Lau, J.; Lundt, B. F.; Petersen, H.; Sørensen, P. O.; Thøgersen, H. The Synthesis of Novel GABA Uptake Inhibitors, Part 2. Synthesis of 5-Hydroxytiagabine, a Human Metabolite of the GABA Reuptake Inhibitor tiagabine. Tetrahedron 1994, 50, 8699-8710.
40. Suzdak, P. D.; Jansen, J. A. A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor. Epilepsia 1995, 36, 612-626.
41. Halonen, T.; Nissinen, J.; Jansen, J. A.; Pitkänen, A. Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus. Eur. J. Pharmacol. 1996, 299, 69-81.
42. Meldrum, B. S. Update on the Mechanism of Action of Antiepileptic Drugs. Epilepsia 1996, 37, S4-S11.
43. Brodie, M. J. Tiagabine Pharmacology in Profile. Epilepsia 1995, 36, S7-S9.
44. Gustavson, L. E.; Mengel, H. B. Pharmacokinetics of Tiagabine, a γ-Aminobutyric Acid-Uptake Inhibitor, in Healthy Subjects After Single and Multiple Doses. Epilepsia 1995, 36, 605-611.
45. Andersen, K. E.; Knutsen, L. J. S.; Sonnewald, U.; Sørensen, P. O. N-Substituted azaheterocyclic carboxylic acids and a pharmaceutical composition. WO 9107389, 1991.
46. Morlacchi, F.; Cardellini, M.; Liberatore, F. Preparation of Unsaturated Heterocyclic Compounds, II. Synthesis of Guvacine. Ann. Chim. 1967, 57, 1456-1461.
47. Akkerman, A. M.; De Jongh, D. K.; Veldstra, H. Synthetic Oxytocics. I. 3-(Piperidyl-(N)-Methyl)indoles and Related Compounds. Rec. Trav. Chim. Pays-Bas 1951, 70, 899-916.
48. Bettoni, G.; Duranti, E.; Tortorella, V. Absolute Configuration and Optical Purity of 3-Substituted Piperidines. Gazz. Chim. liai. 1972, 102, 189-195.
49. Fox, J. L.; Chen, C. H.; Luss, H. R. Chemistry of 1,1-Dioxothiopyrans. 2. Synthesis, Structure, and Properties of 4-Diazo-2,6-diphenyl-4H-thiopyran 1,1-Dioxide. J. Org. Chem. 1986, 51, 3551-3553.
50. 5-1-azabicyclo[4.3.0]nonane. J. Org. Chem. 1972, 37, 1092-1094.
51. Parham, W. E.; Anderson, E. L. The Protection of Hydroxyl Groups. J. Am. Chem. Soc. 1948, 70, 4187-4189.
52. Oppenländer, K.; Fikentscher, R.; Seidl, H.; Witte, C. N-Hydroxyalkyl-N, N-bisarylamine. Liebigs Ann. Chem. 1969, 725, 222-225.
53. Ananthanarayanan, C. V.; Rastogi, S. N.; Srimal, R, C.; Anand, N. Diphenylamino-alkanamines, Alkanamides and ω-Amino-N, N-diphenylalkanamides as Potential Biodynamic Agents. Indian J. Chem. 1974, 12, 31-37.
54. Thoman, C. J.; Hunsberger, S. J.; Hunsberger, I. M. The Chemistry of N-Nitrosoketimines. J. Org. Chem. 1968, 33, 2852-2857.
55. Hixson, S. S.; Franke, L. A. Arylcyclopropane Photochemistry. Effects of Electron-donating and Electron-Withdrawing Aromatic Substituents on the Photochemical Rearrangements of 1,1-Diarylcyclopropanes. J. Org. Chem. 1988, 53, 2706-2711.
56. Buschauer, A. Synthesis and in Vitro Pharmacology of Arpromidine and Related Phenyl(pyridylalkyl)guanidines, a Potential New Class of Positive Inotropic Drugs. J. Med. Chem. 1989, 32, 1963-1970.
57. Ziegler, K.; Späth, A.; Schaaf, E.; Schumann, W.; Winkelmann, E. Die Halogenierung ungesättigter Substanzen in der Allylstellung. Liebigs Ann. Chem. 1942, 551, 80-119.
58. Rylander, P. N. Catalytic Hydrogenation in Organic Syntheses; Academic Press: San Diego, 1979; pp 285-290.
59. Takács, K.; Simay, A.; Harsányi, K.; Korbonits, D. Diphenyl-propylamine Derivatives, IV. Synthesis of N-Methyl-3,3-bis(4-aminophenyl)propylamine. Acta Chim. Acad. Sci. Hung. 1970, 65, 197-201.
60. Knutsen, L. J. S.; Jorgensen, A. S.; Andersen, K. E.; Sonnewald, U. Preparation of N-(aralkoxyalkyl)piperidinecarboxylates and analogues as GABA-uptake inhibitors. EP 374801A, 1989.
61. 3H]-GABA into Rat Brain Synaptosomes. Acta Pharmacol. Toxicol. 1978, 42, 73-76.
62. Nelson, H.; Mandiyan, S.; Nelson, N. Cloning of the Human Brain GABA Transporter. FEBS Lett. 1990, 269, 181-184.
63. Guastella, J.; Nelson, N.; Nelson, H.; Czyzyk, L.; Keynan, S.; Miedel, M. C.; Davidson, N.; Lester, H. A.; Kanner, B. I. Cloning and Expression of a Rat Brain GABA Transporter. Science 1990, 249, 1303-1306.
64. Bowery, N. G. GABA Transporter Protein Cloned from Rat Brain. Trends Pharmacol. Sci. 1990, 11, 435-437.
65. Kuhar, M. A GABA Transporter cDNA has been Cloned. Trends Neurosci. 1990, 13, 473-474.
66. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.